Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21531281 | 1.00 | RIPK1 (0.63) | RIPK1 | |
| SCHEMBL30250600 | 0.87 | RIPK1 (0.59) | RIPK1 | |
| SCHEMBL30250714 | 0.87 | RIPK1 (0.56) | RIPK1 | |
| SCHEMBL30250581 | 0.85 | RIPK1 (0.47) | RIPK1 | |
| SCHEMBL30250620 | 0.85 | RIPK1 (0.55) | RIPK1 | |
| SCHEMBL23075319 | 0.85 | RIPK1 (0.63) | RIPK1 | |
| SCHEMBL23075443 | 0.84 | RIPK1 (0.63) | RIPK1 | |
| SCHEMBL30250593 | 0.82 | RIPK1 (0.47) | RIPK1 | |
| SCHEMBL25077587 | 0.82 | RIPK1 (0.60) | RIPK1 | |
| SCHEMBL30250591 | 0.81 | RIPK1 (0.61) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4025575-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12331036-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4025574-B1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4025572-B1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12116354-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-4304713-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20210009537-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210002237-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210002237-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20200407332-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200407332-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-10815206-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10815206-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190337907-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20240368119-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20210009537-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20200407332-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20210002237-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-12116354-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-12331036-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-20190337907-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-10815206-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.